To evaluate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearing the F and HN glycoproteins of BMV in the background of a recombinant JL5 genome (rMuVJL5). Cross-reactivity and cross-neutralization between this chimeric recombinant MuV bearing the F and HN glycoproteins of BMV (rMuVJL5-F/HNBMV) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of human serum. All mouse and human serum samples that were able to neutralize rMuVJL5 infection had cross-neutralizing activity against rMuVJL5-F/HNBMV. Our data suggest that persons who have neutralizing antibodies against MuV might be protected from infection by BMV.
CITATION STYLE
Beaty, S. M., Nachbagauer, R., Hirsh, A., Vigant, F., Duehr, J., Azarm, K. D., … Lee, B. (2017). Cross-reactive and cross-neutralizing activity of human mumps antibodies against a novel mumps virus from bats. Journal of Infectious Diseases, 215(2), 209–213. https://doi.org/10.1093/infdis/jiw534
Mendeley helps you to discover research relevant for your work.